Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
90Y-hPAM4 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Multi Dose levels | EXPERIMENTAL | different doses of 90YhPAM4 will be given only once. |
| Name | Type | Description |
|---|---|---|
| 90Y-hPAM4 | BIOLOGICAL | Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks. |
Inclusion Criteria: * Male or female patients, \>18 years of age, who are able to understand and give written informed consent. * Histologically or cytologically confirmed, Stage III or IV pancreatic adenocarcinoma. * Patients with Stage III (locally advanced) disease must have documented progressi...
Top 20 of 68 competitors
90Y-hPAM4 is an investigational monoclonal antibody being studied for the treatment of pancreatic cancer. It is a radiolabeled antibody designed to deliver radiation directly to cancer cells. As of the available data, it is in Phase 1 clinical development and has not been approved by regulatory authorities.
90Y-hPAM4 is a monoclonal antibody that targets a specific antigen associated with pancreatic cancer cells. The antibody is labeled with the radioisotope yttrium-90, which delivers targeted radiation to the tumor. This approach aims to concentrate the therapeutic effect at the cancer site while sparing normal tissues.
90Y-hPAM4 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The drug is currently in Phase 1 clinical trials for pancreatic cancer, and its development is part of Gilead's oncology pipeline.
90Y-hPAM4 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory agencies. The Phase 1 trial was designed to evaluate the safety and efficacy of different doses of the drug in patients with pancreatic cancer.
90Y-hPAM4 has one completed clinical trial registered under NCT00597129, titled 'Safety and Efficacy Study of 90Y-hPAM4 at Different Doses.' This Phase 1 study enrolled 21 participants with pancreatic cancer in the United States. The trial was not randomized or blinded and did not use a control group.